Table 2.
Combined Targeted Therapy in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma.
| Combination Regimen | Study | Number of Patients | Treatment-Naïve | ORR (CR) % | Median DOR (mos.) | Median PFS (mos.) | Most Common Grade ≥ 3 AEs | Reference |
|---|---|---|---|---|---|---|---|---|
| Bortezomib, Ibrutinib | Phase I/II | 58 | No | 82 (22) | 22.7 | 18.6 | Thrombocytopenia (16%), Neutropenia (11%), Lung Infections (11%), Neuropathy (9%) | [34] |
| Ibrutinib, Venetoclax | Phase II | 23 | No | 71 (62) | NR | 29.0 | Neutropenia (33%), Thrombocytopenia (17%), Anemia (12%), Diarrhea (12%), Atrial Fibrillation (8%) | [68,69] |
| Ibrutinib, Venetoclax | Phase III | 134 | No | 81 (62) | 42.1 | 31.8 | Neutropenia (31%), Pneumonia (13%), Thrombocytopenia (13%), Anemia (10%), Atrial Fibrillation (5%) | [70] |
| Ibrutinib, Venetoclax, Obinutuzumab | Phase I/II | 24 | No | 71 (67) | NR | NR | Neutropenia (71%), Thrombocytopenia (54%), Hypophosphatemia (29%), Lymphopenia (24%) | [71] |
| 15 | Yes | 93 (86) | NR | NR | ||||
| Acalabrutinib, Venetoclax, Rituximab | Phase I | 21 | Yes | 100 (90) | NR | NR | Infection (38.1%), Neutropenia (33.3%) | [72] |
| Lenalidomide, Venetoclax, Rituximab | Phase II | 28 | Yes | 96 (86) | NR | NR | Neutropenia (75%), Thrombocytopenia (61%), Anemia (32%) | [73] |
| Zanubrutinib, Venetoclax, Obinutuzumab | Phase II | 25 | Yes | 95 (88) | NR | NR | Neutropenia (12%), Infusion-Related Reaction (8%), COVID-19 (8%) | [74] |